Printer Friendly

SALICK HEALTH CARE NAMES DR. ROBERT PETER GALE CORPORATE DIRECTOR OF BONE MARROW AND STEM CELL TRANSPLANTATION PROGRAMS

Appointment of Internationally Acclaimed Physician/Scientist Underscores
 Company's Leadership in Quality, Cost-Effective Cancer Treatment
 LOS ANGELES, July 27 /PRNewswire/ -- Salick Health Care Inc. (NASDAQ: SHCI) today named Robert Peter Gale, M.D., Ph.D., as its corporate director of Bone Marrow and Stem Cell Transplantation Programs. Gale assumes the newly created position Sept. 1. He will expand the company's existing services in these areas while developing national programs for Salick Health Care in the area of new and emerging cancer therapies.
 Gale is an international expert in leukemia and cancer treatment and bone marrow transplantation. He is also widely recognized as the world expert in dealing with radiation accidents. Gale was instrumental in developing the bone marrow transplantation program at the University of California, Los Angeles.
 "Intensive therapy, including bone marrow and stem cell transplantation, is increasingly used to treat cancer," said Gale. "In many instances, these approaches are more effective, and save more lives, than conventional cancer therapy.
 "One of our primary goals is to provide these new medical therapies to the many thousands of persons who need them, in a quality, cost- effective manner. We can accomplish this by consolidating the extensive resources of Salick Health Care and its affiliated medical and scientific network in a nationwide, coordinated bone marrow and stem cell transplant program."
 "The future of cancer treatment lies in innovative approaches such as bone marrow and stem cell transplantation, and in cell and gene therapies," said Dr. Bernard Salick, chairman and chief executive officer of Salick Health Care Inc. "We have already begun providing bone marrow and stem cell transplants at several of our Comprehensive Cancer Centers. Dr. Gale will lead our expansion of these and related activities."
 Gale received his M.D. from the State University of New York and his Ph.D. in immunology from the University of California, Los Angeles. He is the chairman of the Scientific Advisory Committee of the International Bone Marrow Transplant Registry, a scientific network of more than 230 transplant centers worldwide. Gale has published more than 700 scientific papers and 20 books on various medical issues, and also writes on nuclear and Soviet issues. He is most widely known for his leading an international team of scientists and physicians to treat victims of the nuclear accidents in Chernobyl and Brazil.
 Salick Health Care is a leading provider of diagnostic and therapeutic services to patients with complex, chronic illnesses requiring sophisticated long-term care, principally in the areas of cancer, kidney failure, organ transplantation and other immune deficiency diseases. The company provides these services at alternate sites, including outpatient facilities (hospital-based and freestanding), selected inpatient sites and patients' homes.
 Salick currently operates nine Comprehensive Cancer Centers throughout the United States. The company also operates eight outpatient dialysis centers and provides inpatient dialysis services at 21 hospitals. Through its INFUSX subsidiary, Salick provides infusion, nutritional and related services in the patient's home and at specialized outpatient facilities.
 For information on Salick by fax, dial 800-PRO-INFO, ext. 131.
 -0- 7/27/93
 /EDITOR'S NOTE: Dr. Gale bio and photo available by calling The Financial Relations Board at 818-783-2400./
 /CONTACT: Leslie Bell, CFO, executive VP, of Salick Health Care, 213-966-3410; or Nick Farina (Chicago), 312-266-7800, or John H. Shaw (Los Angeles), 818-783-2400, both of The Financial Relations Board, for Salick Health Care/
 (SHCI)


CO: Salick Health Care Inc. ST: California IN: HEA SU: PER

MF-LM -- LA017 -- 6075 07/27/93 09:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1993
Words:571
Previous Article:PASADENA TOURNAMENT OF ROSES SELECTS AMERICAN HONDA TO PROVIDE OFFICIAL VEHICLES
Next Article:CALENDAR CAPITAL, INC. TO OPERATE CRUISE SHIP CASINO IN THE CARIBBEAN
Topics:


Related Articles
SALICK HEALTH CARE POSTS RECORD THIRD QUARTER AND NINE MONTHS 1993 RESULTS
WESTLAKE COMP. CANCER CENTER TO ESTABLISH BONE MARROW TRANSPLANTATION, STEM CELL PHERESIS PROGRAM UNDER DIRECTION OF ROBERT GALE, M.D., PH.D.
SALICK HEALTH CARE AND THE GEORGE WASHINGTON UNIVERSITY ANNOUNCE COMPREHENSIVE CANCER CENTER
SALICK HEALTH CARE ANNOUNCES RECORD FISCAL YEAR 1993 RESULTS
SALICK HEALTH CARE ACHIEVES RECORD FIRST QUARTER RESULTS; NET INCOME ROSE 15 PERCENT FROM PRIOR YEAR
SALICK HEALTH CARE AND VALUE HEALTH SCIENCES CREATE BREAKTHROUGH CANCER TREATMENT GUIDELINES
SALICK HEALTH CARE'S INFUSX ACQUIRES ViCARE, PHILADELPHIA-AREA HOME THERAPY FIRM
United Resource Networks Announces Specialized Pediatric Transplant Network
Nurses are becoming primary educators for expectant moms; Cord Blood Registry.
Open Letter to President Urges Full Exploration of Life Potential, Not Its Negation, Announces Cord Blood Registry.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters